Preventiononly® | Science Without the Soundbites
- Saneka Chakravarty, MD, FACC
- Feb 23
- 4 min read
“Statins only add 4 days after a heart attack.”
What Dr. Asheem Malhotra said on the Joe Rogan podcast and what the science actually means
Recently, cardiologist Dr Asheem Malhotra appeared on The Joe Rogan Experience and made a striking claim: statins only extend life by about four days after a heart attack.
That sentence spread fast. And like many viral medical claims, it is technically grounded in a real scientific paper , but easily misunderstood when taken out of context.
Let’s slow this down, unpack the actual research he’s referring to, and explain , in plain English , what’s great, what’s not so great, and what patients should really take away from this discussion.
Where does the “4 days” number come from?
The claim traces back to a 2015 paper published in BMJ Open by Kristensen and colleagues.
Instead of asking:
“What percent reduction in death did statins provide?” or
“What is the number needed to treat?”
The authors asked a different question:
On average, how much does statin therapy postpone death during the time patients were studied?
Using this method, they found:
~3.2 days of postponed death in primary prevention (people without prior heart attack)
~4.1 days in secondary prevention (people after a heart attack)
This is the statistic Dr. Malhotra referenced.
What’s good about this analysis (and why it resonated)
1. It speaks the language patients actually use
Patients rarely ask about “relative risk reduction.”
They ask: “How much longer will I live?”
The “days of life gained” framing is intuitive and emotionally honest. In that sense, the authors deserve real credit.
2. It highlights time-to-benefit, not just benefit
Statins don’t work overnight. Later studies show:
It takes ~2.5 years of statin use to prevent one major cardiovascular event per 100 people treated
That matters enormously for:
Older adults with limited life expectancy
Patients with advanced illness
People experiencing significant side effects
This analysis reminds clinicians to match treatment to timeline, not just guidelines.
3. The methodology is transparent
The authors calculated the area between survival curves , a legitimate, reproducible statistical approach.
Later meta-analyses using similar methods found slightly larger numbers (closer to 10–12 days), but the general concept held up.
What’s not so great (and where the soundbite goes wrong)
1. Trials are short. Life is long.
Most statin trials lasted 2–6 years.
The analysis only captures:
Death postponed during the trial window
It cannot measure:
Benefits that continue beyond the trial
“Legacy effects” where earlier statin use lowers future risk even after stopping
So the “4 days” is not lifetime benefit , it’s trial-period benefit.
2. Averages hide who actually benefits
This is a huge issue.
A single average combines:
A 40-year-old with minimal risk
A 70-year-old with diabetes and prior heart attack
The analysis showed death postponement ranging from -5 to 19 days in primary prevention, highlighting this heterogeneity.[1]
In the same study:
Some people gained no benefit
Others gained weeks, not days
Averages flatten reality. Medicine is personal.
3. Death is not the only outcome that matters
The paper focused only on mortality.
It did not capture reductions in:
Non-fatal heart attacks
Strokes
Heart failure
Disability
Loss of independence
Avoiding a stroke that leaves someone unable to speak or walk is not trivial , even if it doesn’t change the date on a death certificate.
4. The framing risks discouraging appropriate use
When the message becomes:
“Statins only give you four extra days”
Patients who clearly benefit may stop therapy without realizing:
Their personal benefit may be much larger
The main gain may be avoiding catastrophic events, not extending life by a calendar number
This is where nuance gets lost.
Translating this into plain language
Here’s the simplest way to understand it:
Statins don’t dramatically extend lifespan for everyone
They help the most in people at higher cardiovascular risk
Their biggest value is often preventing heart attacks and strokes , not adding years
They require time to work
They should be used selectively, not reflexively
The BMJ paper doesn’t say statins are useless.
It says: be honest about what they do
and for whom.
Preventiononly® bottom line
Dr. Malhotra is right about one thing:
We need better conversations about benefit, harm, and expectations.
But the “4-day” figure:
Is real, but incomplete
Is provocative, but not personalized
Reflects trial duration, not lifetime impact
Ignores quality of life and non-fatal events
The truth lives between blind enthusiasm and viral dismissal.
Good prevention is not about exaggeration.
It’s about matching the right therapy to the right person at the right time.
References
1. The Effect of Statins on Average Survival in Randomised Trials, an Analysis of End Point Postponement. Kristensen ML, Christensen PM, Hallas J. BMJ Open. 2015;5(9):e007118. doi:10.1136/bmjopen-2014-007118.
2. Legacy Effects of Statins on Cardiovascular and All-Cause Mortality: A Meta-Analysis. Nayak A, Hayen A, Zhu L, et al. BMJ Open. 2018;8(9):e020584. doi:10.1136/bmjopen-2017-020584.
3. Statins and Mortality: The Untold Story. Kostapanos MS, Elisaf MS. British Journal of Clinical Pharmacology. 2017;83(5):938-941. doi:10.1111/bcp.13202.
4. Postponement of Death by Statin Use: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hansen MR, Hróbjartsson A, Pottegård A, et al. Journal of General Internal Medicine. 2019;34(8):1607-1614. doi:10.1007/s11606-019-05024-4.
5. Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. Yourman LC, Cenzer IS, Boscardin WJ, et al. JAMA Internal Medicine. 2021;181(2):179-185. doi:10.1001/jamainternmed.2020.6084.
Comments